NCT03611322 - A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 8, 2018

Primary Completion Date

January 7, 2019

Study Completion Date

January 7, 2019

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide, 0.25 mg

Semaglutide will be administered subcutaneously (s.c., under the skin) on day 1 and 8 in the morning after an overnight fast of at least 8 hours

DRUG

Semaglutide, 0.5 mg

Semaglutide will be administered s.c. (under the skin) on day 15 and 22 in the morning after an overnight fast of at least 8 hours

DRUG

Semaglutide, 1.0 mg

Semaglutide will be administered s.c. (under the skin) on day 29 in the morning after an overnight fast of at least 8 hours

DEVICE

DV3372

DV3372 device will be used for administration of semaglutide

DEVICE

PDS290 pen-injector

PDS290 pen-injector will be used for administration of semaglutide

Trial Locations (1)

Novo Nordisk Investigational Site, Berlin